Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
one of the best articles so far to explain the scenario revolving around CTD
your first two paragraph's are regular jargon.
cool, I wrote it to help everyone out. best of luck
everything depends on your time frame on how you classify things. If you commit capital based on daily charts, it's a break out since it closed above the range. If it went above the range but back into the range all within the same day, it's a failed break out. If it stays above the range for multiple days, but then later falls back into the range on a following day, it's a breakout with no follow through.
How you treat things now is dependent on your risk appetite. If you are just committing capital based on technicals, to enter/add tomorrow is a solid move, but there is no follow through yet, so to manage risk you need to adjust your share size accordingly. If there is follow through, where the next several days we pause here and then have another energy candle to the upside, the next pause is where you can confidently enter with large share size since the stock has followed through and has proven itself to be strong and you will have chart points established which will allow you to manage risk easily, meaning you won't just be entering in the middle of nowhere and where you should get out is obvious.
Given the small down side though at this point, and the positive fundamentals surrounding CTDH, while coupled with news that has a specific time frame attached to it, you can give the stock a little more breathing room to let the scenario play out.
I read taht with Orphan Drug designationt, the FDA may not require Phase III clinical trials since 1000 may not be available. I'm trying to find some sources other than Wiki and About to verify this.
I see now, thank you for helping me understand their role in things.
What I am wondering is people's opinion on ViStra Growth Partners. I have not yet found the correlation between it and CTD's business model, and am trying to find out how it fits into the overall picture of CTD and cyclodextrin manufacturing, maybe it's something totally non-related. I am hoping to see ViSta's business activities reflect positively on the upcoming earning's report. Any ideas? thanks
please keep in mind that it's a otc.bb stock, so company details take a little bit more effort to find than non-otc.bb/.pk stocks. I think your direction is correct in terms of finding out this company specific information, and am trying to find it as well. Digging through earning's reports is definately the first step. good luck
oh sorry, I should have explained. This is the site to check after the 60 days has passed. I'm sure http://addiandcassi.com will announce it right away, but you can use the FDA's site as confirmation, and it can be assumed that institutions will use the FDA's site as confirmation. When the institutions decide to get involved, that's where the real money is... :)
cool, I guess what I am really driving at through is the difference between price and fundamentals (and I think you are too). Fundamentally, CTD has excellent prospects, but it can easily be pointed out that a lot of stocks do not reflect their fundamental value due to the market itself; (market in this sense is the market for the individual stock, not the overall market, which by the way is why I like CTDH, because I do not have to worry about the indices' overall performance affecting CTDH's performance, thefore overall market risk has been effectively eliminated.)
I know many bond traders who were 'right' fundamentally, but lost their company millions because they were 'right' too soon, and a few years after they got fired, their positions finally turned around and now the investment banks they were working for are reaping the rewards.
To put that example into context, we can be either 'right' or 'wrong' to whatever degree we like, but it's market that determines whether the position is profitable or not, I've seen too many traders, in stock's especially, not manage their positions with a clear head because they felt they were 'right'. Of course I'm not looking to sell here; the risk:reward potential is just too good. I risked a few cents to make potentially anywhere between $3.00 to $100.00 in the next 20 years, depending on how things play out, which I will manage. If CTDH went to zero (which is not something I see happening), the only thing I really lost is the commission I paid to make money (which I think everyone else here is in that same good position), and that's not something to sweat, because commission is just an expense for being in business.
Anyways, this post got a little long cause I touched on a lot of topics. Good luck! :)
Here's the link you can use to check the status. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
Next step is to see which pharmaceutical company is going to pick up the benefits of the Orphan Drug Status since it was filed by an individual and hospital, and then see how CTD is increasing its bottom line from those benefits.
just trying to help out. It's always nice to be happy when your stock works out, but if you let it go to your head, it will be detrimental to managing your position correctly. good luck! :)
the market is always right, not you or me.
It's not just a 52 week high, it's better; it's a 5 year high
Don't sell, gotta avoid the tax man!
in Brooklyn? I just moved from Sunset Park
If I wasn't serious I wouldn't be asking
you tell me
huh??
ok, sounds great, another possible market for CTD's product. what info is there that shows CTD is taking advantage of it, or do we just need to wait for a PR statement or earnings report that shows they are taking advantage of it?
money is made in the waiting, not the thinking
needs to cross and hold above .20 to justify an add-on based on techicals, while .05-.10 is more preferable based on a time-frame focused on the FDA decision and beyond that event, which I feel the real money is.
great info! thanks for posting it!
well done! I'm looking to add too with the right price and right info.
oh, I get it now, thanks.
'it's some kind of site that gives reports for all companies'
like I said, I hope something gets filed with the SEC
Please don't turn this thread into a flamey one.
'Relax guys no need to spoil a good day over a simple misunderstanding.'
Ahh, thank you again sashex001.
I am hoping there is some sort of filing with the SEC, it will do much good for CTD
'This is part of the first phase of more interaction with Shareholders...'
I thought you were referring to the Annual Report released today as interaction with shareholders. Anyways, like I said, it doesn't seem that the report was filed with the SEC. I would take it as a positive sign if it was.
'why is that hard to comprehend?'
chill, lets not turn this thread into a flamey one.
it doesn't seem that the report was filed with the SEC. I would take it as a positive sign if it was.
thanks
aahhh, thank you sashex001; it's not Trappsol but Aquaplex needed, which CTD has a patent on. So the other part, is it already decided which pharmaceutical company will have distrubuting rights for 7 years for the proposed drug that CTD would be supplying to?
$1.70, sounds good, but anyways, how do you know it's CTD that will be used to supply the cyclodextrin and not say, Wacker Biochem Corporation, which is located in Michigan?
Perhaps my understanding of the whole situation is wrong, and I invite you to please correct it or fill in the gaps if there are any. To my understanding it's not an open market on orphan drugs and only one company will be used to distrubute the product to the consumers needing it for 7 years (this being done as an incentive for companies to do R&D for the orphan disease since there is only a small market for orphan diseases). CTD is not a pharmaceutical company, but a company that manufactures Trappsol which is their cyclodextrin, hence they won't actually be selling to the consumer but instead supplying cyclodextrin to the medical company that will actually be developing the drug.
So based on my understanding which I just present, and which I ask that you please correct if there's any mistakes in it, my question is, how do we know which company is awarded rights to distrubute the new potential drug, and how do know that it would be CTD that would be the supplier to that company?
friend, I'm asking a question and I'm just showing what my reasoning is based on. Please lets not turn this thread into a flamey one. I'm just trying to get a better perspective on CTDH's potential and want that perspective to be based on facts that are quantifiable. My approach is standard when it comes to looking at this from an investment point of view, so please do not use loaded words like 'half truth' which seem to infer that my reasoning is unorthodox. from what I can tell we're all looking for CTHD to do well, so no need to get hostile. If you don't mind, can you still answer my previous quesstion and explain how it's decided which company will have the rights to sell the medicine if it's approved by the FDA. It's important that CTDH is a supplier to them once FDA passes approval. peace man
if you are an invester in a wholesale/supplier/manufacturing company, you need to follow the retail market that applies to your product. Lots and lots of easy examples out there. CAT and HD both follow IYR since they are both related to the housing sector. DELL often follows BBY since Best Buy sells their products. A lot of electronic products stocks took a hit after Compaq went down. Since CTDH is a manufacturer of cyclodextrin, it's important that they are contracted with the company that will be distrubuting the medication. Take note, CTDH does not hold a monopoly on cyclodextrin. There are many distrubuters of it.
what are you using to get level II on pk/ob stocks?
Trying to get the whole picture here... If everything goes through with the FDA, which pharmaceutical will be distubuting the medicine and which manufacturer will be supplying the cyclodextrin to it? I'm having a hard time finding the answer to these questions. Can someone point me in the right direction to get this type of information in general (I'm not trying to get people to do my D&D)? If we know which company will be selling the actual medicine, and we know that CTDH is its supplier, we can gauge that other company's sales (if they're public), which would help us gauge how much profit CTDH is making/will report on their earnings, which will help forcast a reasonable future share price.
Is some sort of gaurentee that Trappsol will be used in that research instead of Cyclodextrin provided by another company?
Yes, CTDH does have a patent on Trappsol, it's version of Cyclodextrin, but if the FDA grants orphen status, how will we know that CTDH will benefit and not some other company that makes Cyclodextrin?
how 'bout it reach 30.00 monday and announce a 10.00 per share dividend; that would be fun
dangit! my add-on order was never filled during recent pull-back! Now it's going go up with just my original position! :( This is like 'bad' good news, haha.